Medpace is a leading global full-service clinical research organization providing Phase I-IV core development services for drug, biologic, and device programs. With medical and regulatory expertise in multiple therapeutic specialties, - Cardiology, Gastrointestinal, Infectious Disease, Metabolic, Neuroscience, Oncology, Regenerative Medicine, Rare Disease - Medpace has assembled experienced and therapeutically focused teams to execute full service global studies at every level of the company’s operations. Medpace creates strategic therapeutic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development – from program planning and execution to product approval.
Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide. Medpace has 1700+ employees and clinical trial experience in over 45 countries and 6 regions - the US, Europe, Central and Eastern Europe, India, Asia Pacific, and China.
In addition to Phase II-IV development services, Medpace provides Phase I / IIA clinical services from Medpace Clinical Pharmacology, central laboratory and therapeutically specialized testing from Medpace Reference Laboratories, complete bioanalytical services in all stages of drug development from Medpace Bioanalytical Laboratories, and central image management and reading from Medpace Imaging Core Lab.
Medpace was recently recognized as a top service provider in the CRO Quality Benchmark Phase II/III Service Providers 2014 ISR Report, leading all profiled CROs in CRA quality and responsiveness, meeting First Patient/First Visit timelines, low staff turnover, and innovative solutions